Our Success Stories
Smarter healthcare decisions powered by data: Discover our AI-driven use cases
Real-World Evidence, Real-World Impact
Whether you’re a clinician, data lead, market access strategist, or corporate development lead, explore how we’ve helped teams like yours unlock the full value of their data — and transform it into better decisions.
Clinical & Medical
Infectious Diseases
Identifying Drivers of Self-Diagnosis to Enable Over-The-Counter (OTC) Switch
Infectious Diseases
Identifying Drivers of Self-Diagnosis to Enable OTC Switch
Discover how AI helped define differentiating symptoms to support OTC switch approval
Challenge
- Indistinct Symptom Profiles: Easy self-diagnosis is critical for OTC switch, but symptoms overlap with other infectious diseases
- Need for Diagnostic Precision: Facilitate accurate self-diagnosis and define early disease onset
Our Solution
- Machine Learning on Real-World Data: Classification models with interpretability layers to identify key self-diagnosable symptoms
Results and Impact
- Identified 9 differentiating symptoms enabling self-diagnosis
- Provided actionable insights provided supporting regulatory application for OTC switch
Rare Diseases
Predicting the Progression of a Rare Disease
Explore how we stratified patients with a rare disease to inform the optimal initiation of treatment
Challenge
- Variable Disease Phenotypes: This rare disease manifests in diverse phenotypes, leading to early or late progression
- Need for Early Intervention: Identification of patients at risk of rapid decline to guide timely treatment initiation
Our Solution
Applied Data-Driven Disease Modeling using Real-World Data to stratify patients by progression speed and detect early markers of accelerated disease
Results and Impact
- Enabled personalized treatment initiation strategies
- Identified turning points for disease acceleration
- Supported RCT design optimization through disease trajectory simulation
Cardiovascular Diseases
Optimizing Care Pathways for Heart Failure Patients
See how we optimized HF patient stratification to inform care pathways using real-world evidence
Challenge
- Variable Disease Progression: Heart failure progression varies significantly, complicating therapeutic pathways
- Need for Tailored Care: Precisely segment patients to align care strategies with clinical and economic goals
Our Solution
- Data-Driven Clustering: Applied clustering algorithms on US claims data
- Phenotype Stratification: Identified clinically relevant HF phenotypes based on comorbidities and progression patterns
Results and Impact
- Discovered 6 unique HF patient phenotypes with distinct comorbidities and hospitalization risks
- Provided actionable segmentation for clinical decision-making and targeted interventions
Access & Regulatory
Rare Diseases
Extending Randomized Controlled Trials (RCT) Insights to Real-World Outcomes
Cardiovascular Diseases
Simulating Real-World Effectiveness for a New Therapy
Discover how we projected real-world treatment impact before market adoption
Challenge
- New Treatment, Limited Data: A novel therapy had no real-world effectiveness data
- Need for Evidence-Based Positioning: Simulate treatment impact to guide best practices and support prescribers and authorities
Our Solution
Hybrid Real-World Data (RWD) - Randomized Controlled Trials (RCT) Modeling: Estimated survival under standard-of-care using RWD, then applied RCT treatment effects under various therapy positioning scenarios
Results and Impact
Confirmed treatment benefits consistent with RCT outcomes
Identified and highlighted a treatment effect modifier
Provided actionable insights on treatment effectiveness pre market
Rare Diseases
Extending Randomized Controlled Trials (RCT) Insights to Real-World Outcomes
See how we bridged RCT efficacy data to real-world effectiveness to support strategic treatment launch
Challenge
- Fragmented Data Sources: Registries and Real-World Data (RWD) catalogs are scattered, making identification and assessment time-consuming
- Need for Extended Insights: Understand treatment impact on real-world outcomes to anticipate post-authorization studies and prepare launch strategy
Our Solution
External Control Arm (ECA):
- Replicated RCT inclusion/exclusion criteria in external databases
- Weighted ECA to match patient characteristics
- Estimated treatment effect on selected real-world outcomes
Results and Impact
- Implemented automated extraction and structuring from +200k papers, +250 registries, +10k observational studies
- Hazard ratio of 0.33 vs. adjusted ECA → 67% risk reduction over time
- Provided robust evidence supporting launch and regulatory discussions
Data & Digital
Rare Disease
Standardizing Disease Identification: From Local Efforts to Scalable Solutions
Rare Diseases
Standardizing Disease Identification: From Local Efforts to Scalable Solutions
See how we built a scalable Rare Disease Framework to accelerate and harmonize rare disease patient identification across regions
Challenge
- Identification Bottlenecks: Patient identification in rare diseases is slow and fragmented, especially in emerging markets
- Need for Standardization: Harmonize local initiatives to ensure consistent and scalable patient identification
Our Solution
Rare Disease Framework including best practices, code modules, and packages to standardize and accelerate patient identification
Results and Impact
- Reduced project execution time and simplified methodology adoption
- Delivered portable code modules for cross-market application
- Increased homogeneity in technical practices
- Accelerated patient identification consistently across diverse regions
RWD & Registries
AI-Powered Registry Identification
Discover how we streamlined registry identification and assessment to accelerate real-world evidence projects
Challenge
Fragmented Data Sources: Registries and Real-World Data (RWD) catalogs are scattered, making identification and assessment time-consuming
- Need for Relevant Selection: Efficiently identify registries fit for purpose and extract actionable metadata
- Enhanced Assessment: Reliable information on registry scope and quality is critical for research
Our Solution
AI-Driven Web Tool (Centralized platform to identify, assess, and select registries):
- Centralisation: Single access point across RWD catalogs and research databases
- Metadata Extraction: LLMs extract registry details (e.g., name, PICOTS) from abstracts
- Hybrid Search Engine: Semantic + keyword search identifies the most relevant registries
Results and Impact
- Implemented automated extraction and structuring from +200k papers, +250 registries, +10k observational studies
- Identified over 10k unique registries in scientific literature
- Delivered a web interface simplifying registry exploration
- Saved time and improved retrieval, assessment, and actionability of registry data
Corporate Development
Oncology & Immunology
Optimizing Clinical Strategies through Integrated Evidence Generation Planning
Oncology & Immunology
Optimizing Clinical Strategies through Integrated Evidence Generation Planning
See how we clarified evidence needs and operationalized a robust clinical roadmap to optimize strategic decisions
Challenge
- Unclear regulatory and payer requirements
- Difficulty prioritizing indications and investments
- High uncertainty affecting success and asset value
- Fragmented, unaligned evidence activities
Our Solution
- Mapped disease landscape and stakeholder needs
- Defined a targeted product profile (TPP)
- Identified priority gaps and value drivers
- Aligned evidence generation with strategic goals
- Co-built an operational evidence plan
Results and Impact
Enabled significant enhancement of asset value, reduced uncertainty, and accelerated strategic decisions through a clarified, actionable evidence roadmap
Neurology
Rescuing Value from Failed Trials to enable Strategic Acquisitions
See how we helped identify undervalued clinical trial assets by extracting actionable insights from failed clinical studies, enabling targeted acquisition decisions
Challenge
- Phase III trial failed primary endpoint despite Phase II success
- Inconsistent results between phases hard to explain
- Lack of clarity on responsive patient subgroups
- Risk of missing value in an apparently failed asset
Our Solution
- Applied Q-Finder®, a supervised proprietary subgroup discovery algorithm, to explore Phase III data for responder signals
- Combined data insights with expert review and literature
Identified responder profiles with strong efficacy and safety
- Statistically validated hypotheses to define target subgroups
Results and Impact
Helped reveal clinically meaningful subpopulations, unlocking hidden asset value and enabling confident, value-driven acquisition decisions
Dermatology
Optimizing Asset Strategy using Synthetic Control Arms
See how we leveraged external comparators and Real-World Data-driven simulations to clarify asset effectiveness, supporting strategic investment decisions
Challenge
- No active comparator in early-phase trials
- Hard to assess relative efficacy or positioning
- Limited view of competitive landscape and value
- Uncertainty about valuation and regulatory strategy
Our Solution
- Aligned scope with client’s evidence goals
- Mapped external comparators via registry & SLR
- Built synthetic control models for comparisons
- Ensured HTA-readiness and strategic communication
Results and Impact
Clarified therapeutic positioning, reduced uncertainty, and strengthened valuation and negotiation power for informed deal-making
Target Identification
Accelerating Deal Prospecting through AI-Powered Target Screening
See how we accelerated strategic target identification by combining advanced AI-driven technology scouting and data-driven market assessments in an intuitive digital interface
Challenge
- Manual and fragmented scouting workflows
- Late detection of strategic opportunities
- Subjective and inconsistent target evaluation
Our Solution
- Built an AI-powered engine for real-time opportunity detection
- Developed a multi-criteria scoring system for target qualification
- Create a secure, collaborative platform tailored to internal needs
- Integrated continuous user feedback to refine recommendations
Results and Impact
Faster and more objective deal sourcing, reduced cycle times, and improved strategic alignment through automated prospecting
Whether you’re exploring new ways to generate evidence, simulate strategic scenarios, or scale your data capabilities, get in touch, we’re here to
help.